Direct cardiac effects of SGLT2 inhibitors
Abstract Sodium-glucose-cotransporter 2 inhibitors (SGLT2is) demonstrate large
cardiovascular benefit in both diabetic and non-diabetic, acute and chronic heart failure …
cardiovascular benefit in both diabetic and non-diabetic, acute and chronic heart failure …
[HTML][HTML] Cardiac mechanisms of the beneficial effects of SGLT2 inhibitors in heart failure: Evidence for potential off-target effects
Sodium glucose cotransporter 2 inhibitors (SGLT2i) constitute a promising drug treatment for
heart failure patients with either preserved or reduced ejection fraction. Whereas SGLT2i …
heart failure patients with either preserved or reduced ejection fraction. Whereas SGLT2i …
Effect of empagliflozin on worsening heart failure events in patients with heart failure and preserved ejection fraction: EMPEROR-preserved trial
Background: Empagliflozin reduces the risk of cardiovascular death or hospitalization for
heart failure in patients with heart failure with preserved ejection fraction, but additional data …
heart failure in patients with heart failure with preserved ejection fraction, but additional data …
[HTML][HTML] Impact of sodium glucose cotransporter 2 (SGLT2) inhibitors on atherosclerosis: from pharmacology to pre-clinical and clinical therapeutics
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are new oral drugs for the therapy of
patients with type 2 diabetes mellitus (T2DM). Research in the past decade has shown that …
patients with type 2 diabetes mellitus (T2DM). Research in the past decade has shown that …
[HTML][HTML] Current and future therapeutic perspective in chronic heart failure
A Mascolo, G Di Mauro, D Cappetta… - Pharmacological …, 2022 - Elsevier
The incidence of heart failure is primarily flat or declining for a presumably reflecting better
management of cardiovascular diseases, but that of heart failure with preserved ejection …
management of cardiovascular diseases, but that of heart failure with preserved ejection …
Differential pathophysiological mechanisms in heart failure with a reduced or preserved ejection fraction in diabetes
M Packer - Heart Failure, 2021 - jacc.org
Diabetes promotes the development of both heart failure with a reduced ejection fraction
and heart failure with a preserved ejection fraction through diverse mechanisms, which are …
and heart failure with a preserved ejection fraction through diverse mechanisms, which are …
Cardiovascular benefits from gliflozins: effects on endothelial function
T Salvatore, A Caturano, R Galiero, A Di Martino… - Biomedicines, 2021 - mdpi.com
Type 2 diabetes mellitus (T2DM) is a known independent risk factor for atherosclerotic
cardiovascular disease (CVD) and solid epidemiological evidence points to heart failure …
cardiovascular disease (CVD) and solid epidemiological evidence points to heart failure …
Pathophysiological basis of the cardiological benefits of SGLT-2 inhibitors: a narrative review
C Panico, B Bonora, A Camera, NC Chilelli… - Cardiovascular …, 2023 - Springer
In recent years, GLP-1 receptor agonists (GLP-1RA), and SGLT-2 inhibitors (SGLT-2i) have
become available, which have become valuable additions to therapy for type 2 diabetes as …
become available, which have become valuable additions to therapy for type 2 diabetes as …
[HTML][HTML] Dapagliflozin protects the kidney in a non-diabetic model of cardiorenal syndrome
K Urbanek, D Cappetta, G Bellocchio… - Pharmacological …, 2023 - Elsevier
Cardiorenal syndrome encompasses a spectrum of disorders involving heart and kidney
dysfunction, and sharing common risk factors, such as hypertension and diabetes. Clinical …
dysfunction, and sharing common risk factors, such as hypertension and diabetes. Clinical …
Sodium-glucose cotransporter-2 inhibitors: Understanding the mechanisms for therapeutic promise and persisting risks
RJ Perry, GI Shulman - Journal of Biological Chemistry, 2020 - ASBMB
In a healthy person, the kidney filters nearly 200 g of glucose per day, almost all of which is
reabsorbed. The primary transporter responsible for renal glucose reabsorption is sodium …
reabsorbed. The primary transporter responsible for renal glucose reabsorption is sodium …